Drug Discovery & Development | FDA OKs Teva's New Treanda Liquid Formulation Drug Discovery & Development Treanda is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia (CLL). |
